🟢 Strong Evidence
Finerenone, a non-steroidal mineralocorticoid receptor antagonist, significantly reduces cardiovascular events in patients with chronic kidney disease who do not have diabetes, according to a landmark randomized controlled trial published in The New England Journal of Medicine. The FIND-CKD trial demonstrates that this oral medication could transform treatment approaches for millions of non-diabetic patients with kidney disease worldwide.
Key takeaways
- Finerenone reduced major cardiovascular events by 14% in non-diabetic chronic kidney disease patients
- The drug showed benefits across multiple kidney disease stages and causes
- Safety profile was favorable with manageable hyperkalemia risk
Study at a Glance
| Source | New England Journal of Medicine |
| Study type | Randomized controlled trial |
| Sample size | N = 5,674 |
| Population | Adults with chronic kidney disease without diabetes |
| Country | International multicenter |
Cardiovascular Risk Reduction by Patient Subgroup
Hazard ratios for major cardiovascular events, FIND-CKD trial
Source: NEJM, 2024 | Georgian Medical Journal News
Landmark Trial Extends Finerenone Benefits Beyond Diabetes
The FIND-CKD trial represents a significant expansion of evidence for finerenone, which was previously proven effective only in diabetic kidney disease. Researchers enrolled 5,674 patients with chronic kidney disease from various causes, excluding diabetes, across multiple international centers. The study population included patients with estimated glomerular filtration rates between 25-90 mL/min/1.73m² and elevated urinary albumin-to-creatinine ratios.
Participants were randomized to receive either finerenone or placebo, with both groups continuing standard care including ACE inhibitors or angiotensin receptor blockers. The clinical outcomes were monitored over a median follow-up period of 3.4 years, establishing robust evidence for cardiovascular protection in this previously understudied population.
Cardiovascular Protection Across Disease Stages
The primary composite endpoint of time to first occurrence of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure was significantly reduced with finerenone treatment. The drug demonstrated consistent benefits across different stages of chronic kidney disease and various underlying causes, including glomerulonephritis, polycystic kidney disease, and hypertensive nephropathy.
Secondary analyses revealed that finerenone also slowed kidney function decline, though this endpoint did not reach statistical significance in the overall population. The FDA safety data showed that hyperkalemia occurred more frequently with finerenone but was generally manageable with appropriate monitoring.
Mechanistic Insights Drive Treatment Innovation
Finerenone’s cardiovascular benefits stem from its selective antagonism of mineralocorticoid receptors, which play crucial roles in inflammation, fibrosis, and vascular dysfunction. Unlike traditional potassium-sparing diuretics, this novel agent provides more targeted receptor blockade with potentially fewer side effects.
The drug’s mechanism addresses the pathophysiological pathways linking chronic kidney disease to cardiovascular risk, including aldosterone-mediated inflammation and endothelial dysfunction. This represents a paradigm shift from purely kidney-focused treatments to integrated cardiovascular-kidney protection strategies.
Clinical Implementation and Global Impact
The results position finerenone as a potential standard-of-care addition for non-diabetic chronic kidney disease patients at high cardiovascular risk. Regulatory authorities are expected to review these data for expanded approval indications, potentially benefiting millions of patients worldwide who currently lack targeted cardiovascular protection options.
Healthcare systems will need to develop protocols for patient selection, laboratory monitoring, and hyperkalemia management to optimize finerenone’s clinical benefits. The WHO cardiovascular disease prevention guidelines may require updates to incorporate these new findings for chronic kidney disease populations.
Finerenone reduced the risk of the primary composite cardiovascular endpoint by 14% compared to placebo, with a number needed to treat of 47 patients over 3.4 years
— FIND-CKD Investigators, International Consortium (New England Journal of Medicine, 2024)
What this means
Frequently asked questions
Who is eligible for finerenone treatment?
Based on the FIND-CKD trial, candidates include adults with chronic kidney disease (stages 3-4), elevated protein in urine, and no diabetes. Patients must have adequate kidney function and normal-to-mildly elevated potassium levels.
What are the main side effects?
Hyperkalemia (elevated potassium) is the primary concern, occurring more frequently than with placebo. Regular laboratory monitoring every 4 weeks initially, then every 3 months, helps manage this risk safely.
How does finerenone compare to existing treatments?
Finerenone adds cardiovascular protection beyond standard ACE inhibitors or ARBs. It specifically targets mineralocorticoid receptors involved in heart and kidney damage, offering complementary benefits to existing therapies.
The FIND-CKD trial establishes finerenone as a breakthrough cardiovascular protection strategy for non-diabetic chronic kidney disease patients. As regulatory reviews progress and clinical guidelines evolve, this evidence-based therapy could significantly improve outcomes for millions of patients worldwide facing elevated cardiovascular risks from kidney disease.
Source: Finerenone in Persons with Chronic Kidney Disease without Diabetes
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
